vTv Therapeutics Inc. financial data

Symbol
VTVT on Nasdaq
Industry
Pharmaceutical Preparations
Location
3980 Premier Dr, Suite 310, High Point, NC
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 466 % +133%
Debt-to-equity 395 %
Return On Equity -185 % -273%
Return On Assets -47.3 % +45.4%
Operating Margin -2.4K % +99.2%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 22.9M USD +0.69%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1M USD +11011%
Research and Development Expense 11.5M USD -25.8%
General and Administrative Expense 13.5M USD +15.5%
Operating Income (Loss) -24M USD +11.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -22.6M USD +18.1%
Income Tax Expense (Benefit) 100K USD
Net Income (Loss) Attributable to Parent -18.3M USD +14.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 41.6M USD +405%
Accounts Receivable, after Allowance for Credit Loss, Current 242K USD
Assets, Current 43M USD +324%
Property, Plant and Equipment, Net 50K USD -64.3%
Operating Lease, Right-of-Use Asset 156K USD -42.6%
Assets 43.2M USD +189%
Accounts Payable, Current 4.08M USD +65.6%
Contract with Customer, Liability, Current 17K USD 0%
Liabilities, Current 6.42M USD -37.5%
Contract with Customer, Liability, Noncurrent 18.7M USD 0%
Operating Lease, Liability, Noncurrent 32K USD -85%
Liabilities 25.3M USD -14.2%
Retained Earnings (Accumulated Deficit) -296M USD -5.3%
Stockholders' Equity Attributable to Parent 15M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 17.9M USD
Liabilities and Equity 43.2M USD +189%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.34M USD -42%
Net Cash Provided by (Used in) Financing Activities 50.1M USD +325%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 42.8M USD +545%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 41.6M USD +405%
Deferred Tax Assets, Valuation Allowance 29M USD +18.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 29M USD +18.8%
Operating Lease, Liability 213K USD -43.7%
Depreciation 22K USD 0%
Lessee, Operating Lease, Liability, to be Paid 225K USD -46.3%
Property, Plant and Equipment, Gross 604K USD 0%
Operating Lease, Liability, Current 181K USD +9.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 177K USD -8.76%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33K USD -54.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 23.7M USD +16.8%
Preferred Stock, Shares Authorized 50M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.34M USD +59.3%
Interest Expense 13K USD -13.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares